Northrop Grumman reported a 3% increase in sales to $9.0 billion for Q3 2022 compared to $8.7 billion in Q3 2021. Diluted EPS was $5.89, which included a $0.18 unfavorable impact from marketable securities. The company reaffirmed its 2022 guidance for sales, EPS, and transaction-adjusted free cash flow.
Awards totaled $8.7 billion, resulting in a book-to-bill ratio of 0.97 for the quarter and 1.14 year-to-date.
Sales increased by 3 percent, reaching $9.0 billion.
Diluted EPS was $5.89, including a $0.18 unfavorable impact from marketable securities.
Net cash provided by operating activities amounted to $1.3 billion.
The company expects 2022 sales and diluted earnings per share near the low end of our guidance ranges of approximately $36.2 — $36.6 billion and $24.50 — $25.10, respectively. We continue to expect transaction-adjusted free cash flow1 of $1.5 — $1.8 billion based on current tax law, which requires the amortization of current year research and development expenditures over five years.
Visualization of income flow from segment revenue to net income